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Abstract
Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to
have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate
binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders
(calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in
terms of binding of free phosphate. There are, however, a few disadvantages of the two groups. While the
calcium-containing binders are associated with an increased risk of hypercalcaemia, which is dose dependent,
calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from
chronic kidney failure increases from year to year, as a result of increasing prevalence, there is a growing need for
an alternative to existing phosphate binders. The study presented here therefore summarizes available information
for the novel combination preparation OsvaRen® (calcium acetate/magnesium carbonate) as an alternative therapy
to the calcium-free phosphate binder Renagel® (sevelamer-hydrochloride) and to calcium-containing preparations.
The results of this systematic review showed that OsvaRen® is at least equally effective in the regulation of serum
phosphate level as Renagel®. In particular, OsvaRen® shows no clinically relevant difference in terms of the control
of the serum calcium levels compared to Renagel® and thereby does not increase the risk of a hypercalcaemia, in
contrast to pure calcium-based phosphate binders. On the other hand, Renagel® therapy is much more frequently
associated with gastrointestinal side-effects, a tendency to result in higher tablet burden for patients and high
medication costs. The CALMAG study showed that OsvaRen® was at least as effective and safe in terms of
controlling serum phosphate and serum calcium levels as Renagel® while, at the same time, resulting in about
80% lower costs. In addition, OsvaRen® offers a lower risk of hypercalcaemia and associated subsequent costs and
is thereby also superior to pure calcium-containing phosphate binders.
Because of the effectiveness and tolerability of calcium acetate/magnesium carbonate, OsvaRen® offers a clinically
suitable and, at the same time, cost-effective therapeutic option in the therapy of hyperphosphataemia.
Introduction
About 1.8 million people worldwide with chronic kidney
failure undergo dialysis of which almost 90% undergo hae-
modialysis [1,2]. In the case of long-lasting insufficiency,
the kidneys are not able or are not sufficiently able to pur-
ify the blood of the breakdown products of the protein
metabolism (amongst others urea, creatinine and uric
acid). Also, the regulation of electrolytes, water, as well as
the acid-base balance is disturbed. In long-term patients, a
reduced ability to excrete phosphate therefore frequently
results in a rise in the serum phosphate levels [3].
Even modern dialysis procedures cannot completely
eliminate this excess phosphate. At the same time,
untreated hyperphosphataemia is responsible, amongst
other things, for the increased calcification of the blood
vessels and the tissue, so that dialysis patients have a
highly increased risk of serious cardiovascular disorders
(perfusion disorders, cardiovascular events, strokes etc.).
Overall, they have a higher morbidity and mortality risk.
Consequently, in the USA, the increased serum phos-
phate level in dialysis patients contributes to a 20 to 25%
greater death rate as a result of cardiovascular disorders.
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For this reason, patients who are in an advanced stage of
renal insufficiency are given a phosphate binder in addi-
tion to dialysis therapy [4,5].
In Germany, the prevalence of chronic kidney failure
in 2006 was around 92,000, of which about 73% of
patients underwent dialysis [6]. The phosphate binders
available on the market differ considerably. In addition
to the differences in composition and mode of action
of the different compounds, the effectiveness, toler-
ability, and the price of the various products differ to
a great extent. For this reason, looking at the available
therapy options in the area of phosphate binders
from a health economic viewpoint is of particular
importance.
Classification of phosphate binders
In practice, different therapies are used to reduce the
serum phosphate levels, all of which have the common
goal of reducing the phosphate supplied by food. The
commonly acknowledged triad of successful treatment
consists of low phosphate diet, adequate dialysis, as well
as drug therapy using phosphate binders. These sub-
stances bind the phosphate in the intestine, so that it
can then be excreted from the body via the gastrointest-
inal tract, instead of reaching the blood. The first phos-
phate binder came on the market in Germany already in
the 1960s. Since then, new preparations have continu-
ously appeared [4].
Generally, a distinction is made between two different
classes of phosphate binders:
• Calcium-containing phosphate binders
◦ Calcium carbonate (e. g. Calciumacetat-Nefro®,
Calciumacetat Prorenal AM®, Phos-Ex®)
◦ Calcium acetate (e. g. CC-Nefro®, Dreisacarb®,
Calci-Gry®)
• Calcium-free phosphate binders
◦ Aluminum salts (e. g. Phosphonorm®)
◦ Sevelamer hydrochloride (Renagel®)
◦ Sevelamer carbonate (Renvela®)
◦ Lanthanum carbonate (Fosrenol®)
With the introduction of OsvaRen® (calcium acetate/
magnesium carbonate) as a combination preparation, a
new class of phosphate binder was added.
Differences between the different phosphate binders
exist with respect to the clinical efficacy, possible side-
effect profiles, as well as market prices. In the following,
the most popular phosphate binders (classes) are charac-
terized and their respective advantages and disadvantages
are highlighted. However, already at this point, it might
be stated that the ideal preparation which, at the same
time, is effective, tolerated, and also cost-effective does
not currently exist. A summary is presented in tables 1
and 2.
Calcium-containing phosphate binders
This group comprises calcium acetate and calcium carbo-
nate. These compounds are considered to be an effective
as well as cost-effective therapy option and are therefore
the most widely accepted approach for reducing the level
of phosphate in haemodialysis. Compared to calcium car-
bonate, calcium acetate is considered to be more effective
in the binding of phosphate in the intestine. Hypercalcae-
mia and gastrointestinal complaints are the most frequent
side-effects caused by treatment with calcium-containing
phosphate binders. Gastrointestinal side-effects occur
much more rarely, however, in treatment with calcium-
containing phosphate binders than in treatment with seve-
lamer. Nevertheless concerns have been raised in relation
to usual calcium-containing phosphate binders as they
might cause hypercalcaemia. The link with hypercalcaemia
is based on the finding that, in particular in combination
with vitamin D analogues, the calcification process can be
additionally amplified in the vascular system. However, the
evidence for this link is not conclusive as two comprehen-
sive meta-analyses carried out by Navatheen et al (2009)
[7] and Tonelli et al (2010) [8] were not able to show a sig-
nificant correlation between sevelamer and a lower cardio-
vascular calcification as well as lower mortality. For
example, the CARE-2 study [9] showed that with a con-
stant LDL level there was no significant difference in the
progression of cardiovascular calcification between patients
who received a calcium-containing phosphate binder and
patients who received sevelamer. In contrast, the authors
found that calcium-based phosphate binders, in clinical
“head-to-head” study settings, seem to be more effective
than sevelamer in reducing the phosphate levels. Raised
levels of serum phosphate demonstrably represent the
most important independent risk of calcification and mor-
tality in dialysis patients. Apart from calcium acetate and
calcium carbonate, there are only a few calcium-containing
phosphate binders all of which are rarely used [4,7-10].
Calcium-free phosphate binders
Aluminum
Examples of this group are algedrate and the aluminum
chloride hydroxide complex. Aluminum-containing phos-
phate binders are, as a basic rule, very effective but are
only rarely used as they are rather toxic. When used on a
long-term basis, they cause lingering aluminum intoxica-
tion which can be responsible for the inhibition of various
enzyme activities. Distortion of perception, disorders of
bone metablism (osteomalacias), as well as anaemia is a
frequent consequence of long-term application. Clinical
symptoms are diagnosed, even with low dosing regimens,
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so that safe dosing is difficult and use is associated with a
high expenditure in terms of the need for control visits [4].
Sevelamer
Sevelamer hydrochloride is the only synthetically pro-
duced aluminum-free and metal-free phosphate binder
that mainly binds phosphate by means of ion exchange
and hydrogen binding in the duodenum. Sevelamer
hydrochloride has been marketed since 1998 in the US
and Europe under the brand name Renagel® (Genzyme
Corporation). Numerous studies have shown that sevela-
mer is equally effective in phosphate binding as calcium
preparations, but in so doing triggers fewer hypercalcae-
mic episodes. Moreover, it is suspected that sevelamer is
capable of reducing calcification of the heart, as well as
the aorta and, in addition, lowering total cholesterol and
LDL-cholesterol. Clinical studies of sevelamer have
indeed been able to establish a lower rate of hospitaliza-
tion (as a secondary outcome parameter). However, it
has not been possible to demonstrate reduced rates of
mortality or morbidity (as a primary outcome). As seve-
lamer hydrochloride is more costly than calcium-
containing compounds and patients have to take rela-
tively more tablets widespread use of this therapeutic
option is limited. It is additionally suspected that sevela-
mer adversely affects the action of other drugs in that
these are also bound by the polymer and this thereby
reduces the effect of concomitant medications. A new
formulation of sevelamer, sevelamer carbonate, was
licensed in 2009 under the brand name Renvela®. Treat-
ment with sevelamer carbonate appears to cause less
acidosis than treatment with sevelamer hydrochloride
[4,6-8,11].
Lanthanum carbonate
Lanthanum carbonate (Fosrenol® from Shire Pharmaceu-
ticals) is an aluminum-free and calcium-free phosphate
binder which has been available since 2005 in the US and
since 2006 in Europe. Based on evidence gained up until
now, it has the same efficacy with respect to the phos-
phate binding properties as do aluminum-containing pre-
parations, but without the explicit risk of associated
intoxication. Although numerous long-term studies have
produced no evidence of side-effects, it is nevertheless
Table 1 Summary of the advantages and disadvantages of different phosphate binders
Phosphate binder Advantages Disadvantages (limiting factors)
Calcium acetate
(e. g. Calcium acetate Nefro®, Calcium
acetate Prorenal AM®, Phos-Ex®, amongst
others)
• Effectiveness independent of pH value
• Lower calcium uptake compared to calcium
carbonate
• Moderate tablet burden
• Highly cost-effective
• Good tolerability
• Gastrointestinal complaints
• Risk of hypercalcaemia
• In some circumstances, influence on vascular
calcification
Calcium carbonate
(e. g. CC-Nefro®, Dreisacarb®, Calci-Gry®,
amongst others)
• Effective
• Highly cost-effective
• Good tolerability
• Effectiveness influenced by pH value
• Gastrointestinal complaints
• Risk of hypercalcaemia
• In some circumstances, influence on vascular
calcification
Aluminum salts
(e. g. Phosphonorm®)
• High effectiveness independent of pH value
• Highly cost-effective
• High risk of aluminum toxication including
encephalopathy and bone diseases
• Difficulties in relation to precise dosing
• Greater amount of controls
Sevelamer
(Renagel®, Renvela®)
• Effective
• No risk of hypercalcaemia
• Amongst other things, preventative action in
relation to calcification and cholesterol
• Frequent gastrointestinal complaints
• High costs
• High tablet burden, poor compliance
• In some circumstances, negative influence on
other medication (e.g. binding of fat-soluble
vitamins)
Lanthanum carbonate
(Fosrenol®)
• Effectiveness independent of pH value
• No risk of hypercalcaemia
• Low dosage - low tablet burden, improved
compliance
• High costs
• In some circumstances, lanthanum particles can
be reabsorbed from the intestine and reach the
organs
Combination preparation
(OsvaRen®)
• Effectiveness independent of pH value
• Lower calcium uptake and reduced risk of
hypercalcaemia compared to calcium acetate and
calcium carbonate
• Good tolerability
• Moderate tablet burden
• Moderate costs
• In some circumstances, preventative effect in
relation to calcification
• Monitoring of the magnesium level
• In some circumstances, moderate increase in
the serum magnesium level
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suspected that lanthanum particles are reabsorbed via the
intestine and migrate from there out into the tissues of
the organism. Lanthanum carbonate is already very effec-
tive in small dosages (normally one tablet per meal),
whereby patients experience a comparatively low tablet
burden, which is conducive for therapy adherence. How-
ever, lanthanum carbonate comes with comparatively
high costs, as lanthanum is a rare and therefore expensive
metal [4,8].
Phosphate binders with magnesium and reduced
calcium content
OsvaRen® (Fresenius Medical Care), which is the focus of
this study, belongs to this group of phosphate binders.
This comparatively new preparation is an oral phosphate
binder that contains two active compounds - calcium
acetate (in reduced form), as well as magnesium carbo-
nate (Composition: 435 mg calcium acetate (110 mg cal-
cium) and 235 mg magnesium carbonate (60 mg
magnesium)[12]) - which were shown to enable an effec-
tive, safe, and well-tolerated control of serum phosphate
levels in dialysis patients. The potential benefit of this
therapy compared to calcium-based phosphate binders
lies in the reduced daily intake of calcium combined with
a higher phosphate-binding capacity: 1,000 mg OsvaRen®
has a theoretical phosphate-binding capacity of 58.4 mg
phosphate, whereas 1,000 mg calcium acetate or calcium
carbonate only bind 45 mg or 39 mg phosphate, respec-
tively. The reduced daily intake of calcium reduces the
risk of hypercalcaemia. However, a decisive advantage of
Table 2 Brief summary of the different classes of phosphate binders
Property OsvaRen® Renagel®/
Renvela®
e.g. CC-Nefro®,
Dreisacarb®
Active compound
class
Phosphate binder with reduced calcium content and
proportion of magnesium (combination preparation)
Calcium-free
phosphate binder
Calcium-containing phosphate binder
Active compound Calcium acetate/magnesium carbonate Sevelamer
hydrochloride/
Sevelamer
carbonate
Calcium acetate
Calcium carbonate
Licensed October 2007 April 2001/June
2009
Since the late 1980s
Brand name OsvaRen® film tablets Renagel® 800
mg film tablets
Calcium acetate:
Calciumacetat-Nefro®, Calciumacetat
Prorenal AM®, Phos-Ex®, amongst others
Calcium carbonate:
CC-Nefro®, Dreisacarb®, Calci-Gry®,
amongst others
Manufacturer Fresenius Medical Care Genzyme
Corporation
Various
Price/Packaging unit
(Germany)
€ 49.75 [23] € 297.29 [23] • Calciumacetat-Nefro® € 22.68,
• Calciumacetat Prorenal AM® € 18.10,
• Phos-Ex® € 27.69,
• CC-Nefro® € 24.53,
• Dreisacarb® € 24.53,
• Calci-Gry® € 24.57
Dosing
(Film tablets each day
depending on the
serum phosphate level)
3-10 3-15 • Calciumacetat-Nefro® 9-16,
• Calciumacetat Prorenal AM® 9-16,
• Phos-Ex® 8-16,
• CC-Nefro® 12-18,
• Dreisacarb® 6-12,
• Calci-Gry® 1-2
Price/day (Euro) € 0.83 to € 2.76 € 4.95 to
€ 24.77
• Calciumacetat-Nefro® € 1.02-1.82,
• Calciumacetat Prorenal AM® € 0.82-
1.45,
• Phos-Ex® € 1.11-2.22,
• CC-Nefro® € 1.48-2.21,
• Dreisacarb® € 0.74-1.48,
• Calci-Gry® € 0.25-0.50
Treatment cost/year
(Euro)
€ 300 to € 1,000
on average € 650
€ 1,800 to
€ 9,000
on average
€ 5,400
• Calciumacetat-Nefro® € 400-700,
• Calciumacetat Prorenal AM® € 300-
500,
• Phos-Ex® € 400-800,
• CC-Nefro® € 500-800,
• Dreisacarb® € 300-500,
• Calci-Gry® € 100-200
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a combination of calcium and magnesium should be the
positive effect of magnesium on the heart and vessels.
According to retrospective studies, magnesium poten-
tially delays calcification of the vessels in dialysis patients,
but this connection has not yet been evaluated prospec-
tively. An investigation of the long-term effects of a cal-
cium acetate/magnesium carbonate therapy has yet
to be carried out. OsvaRen® is currently licensed in 28
European countries for the therapy of hyperphosphatae-
mia in conjunction with chronic renal failure in dialysis
patients [4,12-14].
Effectiveness and cost-effectiveness of OsvaRen®
vs. Renagel® vs. calcium-containing phosphate
binders
An ideal preparation - which is simultaneously effective,
well-tolerated and, more-over, also cost-effective - does
not currently exist: Aluminum-containing phosphate bin-
ders are very effective but, because of the danger of
chronic intoxication, are no longer recommended for
long-term treatment. Calcium acetate and calcium carbo-
nate are most frequently used. They constitute an effective
therapy for reducing the serum phosphate levels. Because
of the additional daily supply of calcium and the increased
risk of hypercalcaemia, they are discussed controversial.
Sevelamer hydrochloride (Renagel®) and sevelamer carbo-
nate (Renvela®) are the only metal(aluminium)-free phos-
phate binders. Due to the higher tablet burden, because of
the frequent gastrointestinal complaints, and, in particular,
as a result of higher costs, their use is also limited. Lantha-
num carbonate (Fosrenol®) is likewise an expensive phos-
phate binder, as it is a very rare metal.
The effectiveness and tolerability of OsvaRen® were
recently demonstrated in a clinical study which was
carried out in five European countries. Therefore, a
comparison of currently existing information with
respect to the effectiveness and cost-effectiveness for
existing therapies for hyperphosphataemia and Osva-
Ren® can be made. For this, published health eco-
nomic evidence will be described and discussed against
the background of the results of a new clinical study.
Before an indirect comparison between calcium acet-
ate/magnesium carbonate and sevelamer hydrochloride
therapies is made (especially with respect to economic
considerations) an overview of the comparative health
economic studies which have been carried out up until
now is given.
The Huybrechts study for sevelamer
Two systematic reviews [6,15] are available for phos-
phate-binder therapy, both of which come to the conclu-
sion that there is a lack of good studies of phosphate
binders (especially long-term studies with a robust study
design). In addition, the reviews come to the conclusion
that sevelamer hydrochloride offers no benefit compared
to its cost.
Hence, at this point, in particular, attention will be
given to a study by Huybrechts et al [11] carried out
in 2005. In the study, sevelamer was compared with
calcium-containing preparations (calcium acetate and
calcium carbonate) using a disease-simulation model.
Over a time period of one year, the effects of cardiovas-
cular conditions on life expectancy and the costs of medi-
cal care with sevelamer hydrochloride treatment
were considered. The focus was to thereby evaluate non-
inferiority of sevelamer hydrochloride therapy compared
with calcium-containing preparations.
According to the results of this study, the calcification
index fell within a year in the sevelamer group from
1,502 to 1,362 mg/dl, whereas, in contrast, the value in
the calcium acetate group rose to 1,557 mg/dl. Accord-
ingly, sevelamer hydrochloride treated patients (when
compared to calcium treatment) had a reduced risk of
calcification of 13% after one year. Also, the risk of
severe cardiovascular events was about 12% lower com-
pared to a calcium therapy. The study showed that, in a
population of 100 patients, sevelamer prevented nine
cardiovascular events, on average. This means that with
eleven treated patients, one cardiovascular incident
could be averted.
The most important component of overall costs of each
therapy option was resource use due to inpatient treat-
ment of cardiovascular events. In the sevelamer group,
these represent about 74% and, in the calcium acetate
group about 86% of overall costs. Huybrechts et al stated
that the relatively higher costs of sevelamer therapy are
almost offset by the prevention of nine cardiovascular
events (which is associated with a saving of 200,000 USD
in that study). This leads to cost-effectiveness ratio of
less than 2,500 USD per (discounted) life year gained and
about 4,500 USD per prevented cardiovascular event.
The costs were estimated from a health insurance per-
spective on the basis of US specific resource consump-
tion data. The methods are not described in further
detail in the publication.
Although both investigated phosphate binders produced
almost equivalent results with regard to the phosphate
binding capabilities, Huybrechts et al concluded that the
advantage of sevelamer potentially lies in its ability to slow
down the process of cardiovascular calcification, from
which the authors expect both positive clinical as well as
economic effects.
In summary, the study therefore showed that sevelamer
is not inferior compared to calcium therapy and, more-
over, is effective in the prevention of cardiovascular
events, the result of which is that overall costs could
potentially be reduced. Finally, it should be mentioned
that Huybrechts et al (2005) used a complex and modular
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model that follows individual patients via a discrete event
simulation technique estimating both, one year as well as
the long-term effects. The algorithms used were not
completely disclosed in the publication.
Studies of OsvaRen®
OsvaRen® vs. Renagel® (CALMAG study)
The CALMAG (CALcium acetate-MAGnesium carbo-
nate evaluation) study was a 24-week, randomized, con-
trolled, multicenter parallel group study carried out in
five European countries which compared the efficacy of
the two phosphate binders: calcium acetate/magnesium
carbonate (OsvaRen®) and sevelamer hydrochloride
(Renagel®). The aim of the study was to determine
whether OsvaRen® therapy is equally effective in redu-
cing the serum phosphate levels in haemodialysis
patients as treatment with Renagel® [12]. Of the 255
subjects who were included in the CALMAG study, 204
patients completed the trial. The remaining participants
dropped out during the study for various reasons. The
study population was divided into an OsvaRen® group
with 105 patients (drop outs n = 18) and a Renagel®
group with 99 patients (drop outs n = 34).
The results of the CALMAG study are presented in
summary form in the next section. Figure 1 shows that
a reduction in the serum phosphate levels was achieved
with both preparations following a 24-week application.
In the calcium acetate/magnesium carbonate group, the
serum phosphate levels could be lowered to the clini-
cally relevant K/DOQI target range already after four
weeks of OsvaRen® therapy whereas, in contrast, in the
sevelamer hydrochloride group this value remained at a
comparatively higher level beyond the total duration of
the study and was first achieved in week 24. Further-
more, OsvaRen® showed a significantly higher reduction
in phosphate levels in the long-term and a better main-
tenance of serum phosphate levels in the K/DOQI target
range was achieved.
Compared to the sevelamer hydrochloride group
serum calcium levels in the calcium acetate/magnesium
carbonate group were slightly increased over almost the
whole time span, but the K/DOQI target value was at
no time exceeded. In addition, with regard to the
ionised serum calcium, there was no significant differ-
ence between the calcium acetate/magnesium carbonate
and the sevelamer hydrochloride group. Hence, with
regard to the control of the serum calcium levels and
the risk of hypercalcaemia, no clinically relevant differ-
ence between the calcium acetate/magnesium carbonate
group and the sevelamer hydrochloride group was
reported. Following these outcomes, it can be concluded
that treatment with calcium acetate/magnesium carbo-
nate does not lead to an increased risk of hypercalcae-
mia compared to sevelamer hydrochloride.
Serum magnesium levels in the calcium acetate/mag-
nesium carbonate group were as expected slightly
increased. Symptoms associated with raised magnesium
levels, however, did not appear during the study. In
adults, the normal level for serum magnesium ranges
between 0.7 and 1.1 mmol/l such that, especially in the
case of haemodialyis patients, there is frequently a slight
increase of these values. In recent years, a number of
studies have shown that higher and increased serum
magnesium levels in dialysis patients are associated with
positive cardiovascular characteristics, such as, an anti-
calcification effect as well as improved survival [16-22].
According to the label information, OsvaRen® is only
contraindicated in patients with a serum magnesium
level of more than 2 mmol/l.
Therefore, the CALMAG study came to the conclusion
that, with regard to the primary endpoint - i.e. the reduc-
tion in the phosphate level-; OsvaRen® is at least as effec-
tive as Renagel®. Moreover, OsvaRen® was shown to be
superior in achieving and maintainting levels of serum
phosphate within the K/DOQI target range and proved
to be comparable in maintaining serum calcium levels
within the K/DOQI target range. Finally, with OsvaRen®,
gastrointestinal complaints were reduced by about 50%
compared with Renagel® [12].
OsvaRen® vs. calcium-containing phosphate binders - the
Deuber study
Because of the addition of magnesium, which also acts as a
phosphate binder, OsvaRen® also shows an improved
phosphate-binding capacity compared to pure calcium-
containing phosphate binders in combination with a
reduced daily calcium intake. Compared to a calcium acet-
ate tablet of 660 mg (corresponding to 167 mg elemental
calcium), OsvaRen® as a combination preparation con-
tains 35% less elemental calcium. However, as a conse-
quence of its magnesium component, OsvaRen® has a
30% higher phosphate-binding capacity per film tablets
Figure 1 Serum phosphate level [12].
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compared to pure calcium acetate (39.1 mg vs. 29.7 mg).
Compared to a calcium carbonate tablet of 500 mg (corre-
sponding to 200 mg elemental calcium), calcium acetate/
magnesium carbonate (following conversion to a compar-
able dose of 670 mg) contains 59% less elemental calcium.
At the same time the combination formulation has,
because of the magnesium component, a 50% higher phos-
phate-binding capacity per film tablet than pure calcium
carbonate (39.1 mg vs. 19.5 mg) [14].
The advantage of a calcium acetate/magnesium carbo-
nate therapy compared to calcium-containing phosphate
binders was established already in 2004 in a 36-month
randomized, controlled clinical study [23] in which 50
haemodialysis patients were subjected to either a calcium
carbonate monotherapy or a combination preparation
consisting of calcium acetate/magnesium carbonate. The
focus of that study was the change in the serum calcium,
serum phosphate, and serum magnesium levels over the
course of time. The data obtained from the study demon-
strated that the combination preparation produced a sig-
nificant and sustained reduction in both the phosphate
level in the blood, and the serum calcium concentration.
In contrast, there was an increase in the serum magne-
sium level which, however, did not exceed the normal
value for adults and therefore was not critical.
Deuber was therefore able to demonstrate that the
combination of calcium acetate and magnesium carbo-
nate is superior in reducing the serum phosphate levels
compared to calcium monotherapy, particularly since
OsvaRen® can be given in higher doses without causing
any relevant increase in serum calcium [23]. Due to the
better long-term control of the serum calcium level,
OsvaRen® contributes to a reduction in the frequency of
hypercalcaemic episodes and thus also the associated
subsequent costs [24].
Conclusions
OsvaRen® offers an innovative preparation for effective
long-term treatment of a raised serum phosphate level in
patients with chronic kidney failure. From the clinical per-
spective, OsvaRen® is at least as effective in terms of phos-
phate binding as sevelamer hydrochloride (Renagel®) and
is superior compared to calcium-containing preparations.
The analyses of the CALMAG and Deuber studies confirm
the superiority of the combination preparation. OsvaRen®
therefore should be preferred to a calcium carbonate treat-
ment, as it is more effective in achieving the K/DOQI tar-
get values for serum phosphate and especially serum
calcium, and thereby reducing the risk of hypercalcae-mia.
Although OsvaRen® and Renagel® achieved similar
results in reaching the primary endpoint - i.e. the reduc-
tion of serum phosphate levels - there are some arguments
that OsvaRen® might offer a valid therapeutic alternative
versus Renagel®: The evidence has shown that when Osva-
Ren® is compared with Renagel® the target range for
serum phosphate defined in the K/DOQI guidelines can
more rapidly be achieved. In addition, it is equally good at
achieving the levels for serum calcium and therefore, in
summary, to act preventatively with regard to the excess
morbidity and mortality of haemodialysis patients.
In addition to the positive effect of the magnesium com-
ponent, the high phosphate binding capacity and the abil-
ity to slow the possible mechanism of the vessel
calcification process OsvaRen® therapy has a decisive
influence on the overall costs associated with these thera-
peutic options. Because of the price difference between
OsvaRen® and Renagel® (OsvaRen® has about 85% lower
acquisition costs), the conclusions from the Huybrecht
study regarding the economic advantages of Renagel®
treatment from the perspective of the health insurance
have to be reconsidered with the data for OsvaRen®,
which was not included in that analysis.
Figure 2 shows in schematic form how OsvaRen®
might be optimally included in phosphate binding ther-
apy. Because of its clinical properties offering an at least
non-inferior clinical profile combined with an economic
superiority, OsvaRen® can be recommended as a cost-
effective, first-line treatment both for patients who
receive a phosphate binder for the first time, as well as
also for all patients who, up until now, have received a
pure calcium-based phosphate binder or calcium-free
phosphate binders.
Within the German health care setting, the benefit to
a patient is considered to be an improvement in the
state of health, a reduction in the duration of the illness,
an increase in life time, a reduction in side-effects, as
well as an improvement in the quality of life. From the
perspective of the Institute for Quality and Efficiency in
Health Care (IQWiG), this corresponds to a (positive)
impact on the primary outcome parameters (combined
with a safe risk-benefit profile):
• mortality and
• morbidity and
• health-related quality of life.
OsvaRen®, in this respect, is able to fulfil the target
parameters of the IQWiG, because of the reduction in
adverse drug reactions (reduced risk of hypercalcaemia)
as well as an improvement in the health-related quality
of life. Because of the efficacy and tolerability profile of
OsvaRen®, the preparation is a medically suitable and,
at the same time, a cost-effective solution for the ther-
apy of hyperphosphataemia. Therefore, it can be recom-
mended to use OsvaRen® as a first-line treatment
option in the treatment of hyperphosphataemia.
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